NO309123B1 - Fremgangsmate for fremstilling av en biologisk aktiv myseproteinblanding - Google Patents
Fremgangsmate for fremstilling av en biologisk aktiv myseproteinblanding Download PDFInfo
- Publication number
- NO309123B1 NO309123B1 NO19894693A NO894693A NO309123B1 NO 309123 B1 NO309123 B1 NO 309123B1 NO 19894693 A NO19894693 A NO 19894693A NO 894693 A NO894693 A NO 894693A NO 309123 B1 NO309123 B1 NO 309123B1
- Authority
- NO
- Norway
- Prior art keywords
- whey
- protein
- whey protein
- milk
- protein concentrate
- Prior art date
Links
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 231
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 218
- 235000021119 whey protein Nutrition 0.000 title claims abstract description 163
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 235000018102 proteins Nutrition 0.000 claims abstract description 118
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 118
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 118
- 239000012141 concentrate Substances 0.000 claims abstract description 73
- 239000005862 Whey Substances 0.000 claims abstract description 69
- 235000013336 milk Nutrition 0.000 claims abstract description 52
- 210000004080 milk Anatomy 0.000 claims abstract description 52
- 239000008267 milk Substances 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 44
- 238000004925 denaturation Methods 0.000 claims abstract description 24
- 230000036425 denaturation Effects 0.000 claims abstract description 24
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 17
- 239000012528 membrane Substances 0.000 claims abstract description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 12
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000004310 lactic acid Substances 0.000 claims abstract description 7
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 7
- 238000001556 precipitation Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 25
- 241001494479 Pecora Species 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 18
- 102000004407 Lactalbumin Human genes 0.000 claims description 13
- 108090000942 Lactalbumin Proteins 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 235000004252 protein component Nutrition 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000000975 co-precipitation Methods 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 18
- 235000013351 cheese Nutrition 0.000 abstract description 11
- 229940108461 rennet Drugs 0.000 abstract description 5
- 108010058314 rennet Proteins 0.000 abstract description 5
- 102000008192 Lactoglobulins Human genes 0.000 abstract description 4
- 108010060630 Lactoglobulins Proteins 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 238000009928 pasteurization Methods 0.000 abstract description 3
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 238000007669 thermal treatment Methods 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 208
- 235000005911 diet Nutrition 0.000 description 128
- 241000699670 Mus sp. Species 0.000 description 108
- 229960003180 glutathione Drugs 0.000 description 103
- 230000037213 diet Effects 0.000 description 102
- 108010024636 Glutathione Proteins 0.000 description 64
- 235000008504 concentrate Nutrition 0.000 description 59
- 102000011632 Caseins Human genes 0.000 description 52
- 108010076119 Caseins Proteins 0.000 description 52
- 235000021240 caseins Nutrition 0.000 description 52
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 51
- 239000005018 casein Substances 0.000 description 43
- 230000000694 effects Effects 0.000 description 39
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 36
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 33
- 235000018417 cysteine Nutrition 0.000 description 33
- 235000016709 nutrition Nutrition 0.000 description 32
- 230000002766 immunoenhancing effect Effects 0.000 description 30
- 230000000378 dietary effect Effects 0.000 description 26
- 230000028993 immune response Effects 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000003743 erythrocyte Anatomy 0.000 description 18
- 229940088594 vitamin Drugs 0.000 description 18
- 229930003231 vitamin Natural products 0.000 description 18
- 235000013343 vitamin Nutrition 0.000 description 18
- 239000011782 vitamin Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 15
- 108010000912 Egg Proteins Proteins 0.000 description 14
- 102000002322 Egg Proteins Human genes 0.000 description 14
- 235000021245 dietary protein Nutrition 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 230000028996 humoral immune response Effects 0.000 description 13
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 10
- 102000015781 Dietary Proteins Human genes 0.000 description 10
- 108010010256 Dietary Proteins Proteins 0.000 description 10
- 102100032249 Dystonin Human genes 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000003393 splenic effect Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 229940021722 caseins Drugs 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 229960002477 riboflavin Drugs 0.000 description 9
- 208000002720 Malnutrition Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000014105 formulated food Nutrition 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 235000019164 vitamin B2 Nutrition 0.000 description 8
- 239000011716 vitamin B2 Substances 0.000 description 8
- 102000014171 Milk Proteins Human genes 0.000 description 7
- 108010011756 Milk Proteins Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000021239 milk protein Nutrition 0.000 description 7
- 208000015380 nutritional deficiency disease Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010053070 Glutathione Disulfide Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 206010022678 Intestinal infections Diseases 0.000 description 6
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 6
- 229930003471 Vitamin B2 Natural products 0.000 description 6
- 235000020247 cow milk Nutrition 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003797 essential amino acid Substances 0.000 description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229940090044 injection Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 208000035109 Pneumococcal Infections Diseases 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- 235000020776 essential amino acid Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 235000000824 malnutrition Nutrition 0.000 description 5
- 230000001071 malnutrition Effects 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 229940001941 soy protein Drugs 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010028690 Fish Proteins Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241000408529 Libra Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- -1 glycylmonomethyl Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000021332 multicellular organism growth Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000008939 whole milk Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 241000620196 Arthrospira maxima Species 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000195663 Scenedesmus Species 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000014048 cultured milk product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- WLDRFJDGKMTPPV-UHFFFAOYSA-N 1,2-dimethylhydrazine dihydrochloride Chemical compound Cl.Cl.CNNC WLDRFJDGKMTPPV-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- DXLXRNZCYAYUED-UHFFFAOYSA-N 4-[2-[4-(3-quinolin-4-ylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=CC=1OCCN1CCOCC1 DXLXRNZCYAYUED-UHFFFAOYSA-N 0.000 description 1
- 102100025908 5-oxoprolinase Human genes 0.000 description 1
- 108090000900 5-oxoprolinase (ATP-hydrolyzing) Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010001949 Algal Proteins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100116390 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ded1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100033055 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940050447 acetaminophen injection Drugs 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005929 chemotherapeutic response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000012031 short term test Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000008427 tissue turnover Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28997188A | 1988-12-23 | 1988-12-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO894693D0 NO894693D0 (no) | 1989-11-24 |
| NO894693L NO894693L (no) | 1990-06-25 |
| NO309123B1 true NO309123B1 (no) | 2000-12-18 |
Family
ID=23113981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19894693A NO309123B1 (no) | 1988-12-23 | 1989-11-24 | Fremgangsmate for fremstilling av en biologisk aktiv myseproteinblanding |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP0375852B1 (de) |
| JP (1) | JPH03139245A (de) |
| CN (2) | CN1044659A (de) |
| AT (2) | ATE123924T1 (de) |
| AU (1) | AU638439B2 (de) |
| BR (2) | BR8906661A (de) |
| CA (2) | CA1338682C (de) |
| DE (2) | DE68923162D1 (de) |
| DK (1) | DK591589A (de) |
| ES (1) | ES2082762T3 (de) |
| NO (1) | NO309123B1 (de) |
| NZ (1) | NZ231865A (de) |
| PT (2) | PT92698B (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5456924A (en) * | 1988-12-23 | 1995-10-10 | Immunotec Research Corporation Ltd. | Method of treatment of HIV-seropositive individuals with dietary whey proteins |
| AUPN271295A0 (en) * | 1995-05-02 | 1995-05-25 | Gropep Pty Ltd | Method of treatment |
| ATE287415T1 (de) * | 1990-07-13 | 2005-02-15 | Gropep Ltd | Wachstumsfördernder wirkstoff |
| ATE144142T1 (de) * | 1991-01-10 | 1996-11-15 | Transcend Therapeutics Inc | Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen |
| DK0502313T3 (da) * | 1991-02-04 | 1998-02-02 | Nestle Sa | Fremgangsmåde til sikring af tilstrækkeligt intracellulært glutathion i væv |
| US5747459A (en) * | 1991-02-04 | 1998-05-05 | Nestec, Ltd. | Method for insuring adequate intracellular glutathione in tissue |
| DK149591A (da) * | 1991-08-22 | 1993-03-19 | Lube As | Proteinpraeparat |
| US5430045A (en) * | 1992-04-23 | 1995-07-04 | Free Radical Sciences, Inc. | Method of reducing or preventing bone marrow hypoplasia |
| SE470375B (sv) * | 1992-05-07 | 1994-02-07 | Alfa Laval Food Eng Ab | Sätt att erhålla högvärdiga proteinprodukter ur vassle |
| IL106576A (en) * | 1992-08-13 | 2000-08-13 | Immunotec Res Corp Ltd | Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer |
| AU6060694A (en) * | 1993-05-10 | 1994-11-17 | Transcend Therapeutics, Inc | Method for treating acquired immune deficiency syndrome |
| US5447712A (en) * | 1993-12-09 | 1995-09-05 | Free Radical Sciences | Method of reducing cyclophosphamide induced hemorrhagic cystitis |
| ZA949789B (en) * | 1993-12-30 | 1995-10-25 | Immunotec Res Corp Ltd | Process for making undenatured whey protein concentrate |
| WO1998031377A1 (en) * | 1997-01-20 | 1998-07-23 | Mohammed Essaidi | Use of food products for protection against radicals |
| US6333047B1 (en) | 1997-05-09 | 2001-12-25 | Daiichi Kasei Co., Ltd. | Molded capsule superior in strength and stability and method for preparing same |
| JP3188649B2 (ja) * | 1997-05-09 | 2001-07-16 | 株式会社第一化成 | カプセル |
| EP1094824B1 (de) * | 1998-06-10 | 2006-04-05 | Albert B. Crum | Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems |
| MXPA02007491A (es) * | 2000-02-04 | 2002-12-13 | Nestle Sa | Metodo para mantener o mejorar la sintesis de mucinas. |
| JP2006219458A (ja) * | 2005-02-14 | 2006-08-24 | Meiji Milk Prod Co Ltd | 虚血性腸疾患抑制剤 |
| US7572474B2 (en) | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
| US8075934B2 (en) | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
| CA2687427A1 (en) * | 2007-05-04 | 2008-11-13 | Bopa Ireland Limited | A composition for increasing stamina |
| TWI515005B (zh) * | 2008-09-12 | 2016-01-01 | ２４５８７８１加拿大公司 | 在接受化療或放療的患者中應用富含半胱胺酸之乳清衍生蛋白以增進患者存活時間 |
| US8350006B2 (en) | 2008-10-24 | 2013-01-08 | Mead Johnson Nutrition Company | Methods for determining the bioactivity of TGF-β in a composition |
| US8367354B2 (en) | 2008-10-24 | 2013-02-05 | Mead Johnson Nutrition Company | Methods for determining the levels of TGF-β in a composition |
| US8986769B2 (en) | 2008-10-24 | 2015-03-24 | Mead Johnson Nutrition Company | Methods for preserving endogenous TGF-β |
| JP2009137982A (ja) * | 2009-01-05 | 2009-06-25 | Morinaga Milk Ind Co Ltd | インターロイキン−１８誘導剤 |
| WO2013080911A1 (ja) * | 2011-11-30 | 2013-06-06 | 株式会社明治 | 腸内菌叢改善用栄養組成物 |
| CN102998427B (zh) * | 2013-01-20 | 2016-05-04 | 黑龙江省乳品工业技术开发中心 | 牛乳婴幼儿配方粉总乳清蛋白测定时数据的校正处理方法 |
| US9345741B2 (en) * | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
| CN104304642B (zh) * | 2014-10-09 | 2017-06-06 | 光明乳业股份有限公司 | 一种浓缩型乳清蛋白wpc80及其制备方法 |
| CN105660867B (zh) * | 2016-02-18 | 2019-07-30 | 济南大学 | 一种谷胱甘肽酸奶肽片及其制备方法 |
| WO2018057514A1 (en) | 2016-09-23 | 2018-03-29 | Immunotec Inc. | Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders |
| CA2970699A1 (en) | 2017-06-14 | 2018-12-14 | Elizabeth E. Ignowski | Compositions for increasing resilience to traumatic brain injury |
| WO2019027974A1 (en) | 2017-07-31 | 2019-02-07 | Immunotec Inc. | COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER |
| MA52031B1 (fr) | 2019-05-17 | 2022-06-30 | Darbos Atlantic S L | Procede de preparation d'un hydrolysat de proteines a partir d'une matiere premiere d'origine animale |
| CN115005337B (zh) * | 2022-07-08 | 2024-02-27 | 睿迪生物科技（深圳）有限公司 | 一种无菌实验幼猪专用人工乳及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3406076A (en) * | 1965-09-15 | 1968-10-15 | Battelle Development Corp | Process for making cheese by coagulating milk at a low temperature |
| FR2296428A1 (fr) * | 1975-01-03 | 1976-07-30 | Baignes Ste Radegonde Laiterie | Composition de proteines a usage dietetique et therapeutique chez le nourrisson, l'enfant et l'adulte |
| GB1495940A (en) * | 1975-02-18 | 1977-12-21 | Grindstedvaerket As | Anti-cancer active whey fraction |
| FR2459619B1 (fr) * | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| EP0129418B1 (de) * | 1983-06-16 | 1988-10-05 | Farley Health Products Limited | Säuglingsnahrung |
| NL8403433A (nl) * | 1984-11-09 | 1986-06-02 | Holland Melkunie | Voedingssuppletiepreparaat op basis van melkbestanddelen. |
| US4834974A (en) * | 1986-01-13 | 1989-05-30 | Protein Technologies, Inc. | Immunologically active whey fraction and recovery process |
| US4710489A (en) * | 1985-04-22 | 1987-12-01 | Cornell Research Foundation, Inc. | Glutathione delivery system |
| NZ224615A (en) * | 1987-05-14 | 1990-04-26 | Commw Scient Ind Res Org | Process for the production of whey protein fractions |
| GB8729031D0 (en) * | 1987-12-11 | 1988-01-27 | Express Foods Group Ltd | Isolation of immunoglobulin rich fraction from whey |
-
1989
- 1989-09-28 CA CA000614239A patent/CA1338682C/en not_active Expired - Lifetime
- 1989-10-03 AT AT89118344T patent/ATE123924T1/de not_active IP Right Cessation
- 1989-10-03 DE DE68923162T patent/DE68923162D1/de not_active Expired - Lifetime
- 1989-10-03 EP EP89118345A patent/EP0375852B1/de not_active Expired - Lifetime
- 1989-10-03 DE DE68924142T patent/DE68924142T2/de not_active Expired - Lifetime
- 1989-10-03 AT AT89118345T patent/ATE127321T1/de not_active IP Right Cessation
- 1989-10-03 ES ES89118345T patent/ES2082762T3/es not_active Expired - Lifetime
- 1989-10-03 EP EP89118344A patent/EP0374390B1/de not_active Expired - Lifetime
- 1989-11-24 DK DK591589A patent/DK591589A/da not_active Application Discontinuation
- 1989-11-24 NO NO19894693A patent/NO309123B1/no not_active IP Right Cessation
- 1989-12-12 AU AU46701/89A patent/AU638439B2/en not_active Expired
- 1989-12-18 CA CA002005779A patent/CA2005779A1/en not_active Abandoned
- 1989-12-19 NZ NZ231865A patent/NZ231865A/en unknown
- 1989-12-21 BR BR898906661A patent/BR8906661A/pt not_active Application Discontinuation
- 1989-12-22 PT PT92698A patent/PT92698B/pt not_active IP Right Cessation
- 1989-12-22 CN CN89109444A patent/CN1044659A/zh active Pending
- 1989-12-22 PT PT92697A patent/PT92697B/pt not_active IP Right Cessation
- 1989-12-22 BR BR898906704A patent/BR8906704A/pt not_active Application Discontinuation
- 1989-12-22 CN CN89109445A patent/CN1044660A/zh active Pending
- 1989-12-25 JP JP1336200A patent/JPH03139245A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE123924T1 (de) | 1995-07-15 |
| CN1044659A (zh) | 1990-08-15 |
| CN1044660A (zh) | 1990-08-15 |
| ATE127321T1 (de) | 1995-09-15 |
| EP0374390B1 (de) | 1995-06-21 |
| CA1338682C (en) | 1996-10-29 |
| DE68924142D1 (de) | 1995-10-12 |
| PT92698B (pt) | 1995-09-12 |
| NZ231865A (en) | 1994-02-25 |
| NO894693D0 (no) | 1989-11-24 |
| DK591589D0 (da) | 1989-11-24 |
| DE68924142T2 (de) | 1996-02-01 |
| BR8906661A (pt) | 1990-09-11 |
| ES2082762T3 (es) | 1996-04-01 |
| NO894693L (no) | 1990-06-25 |
| DK591589A (da) | 1990-06-25 |
| PT92697B (pt) | 1995-09-12 |
| JPH03139245A (ja) | 1991-06-13 |
| AU4670189A (en) | 1990-06-28 |
| PT92697A (pt) | 1990-06-29 |
| DE68923162D1 (de) | 1995-07-27 |
| PT92698A (pt) | 1990-06-29 |
| EP0375852A1 (de) | 1990-07-04 |
| EP0374390A1 (de) | 1990-06-27 |
| BR8906704A (pt) | 1990-09-11 |
| AU638439B2 (en) | 1993-07-01 |
| EP0375852B1 (de) | 1995-09-06 |
| CA2005779A1 (en) | 1990-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309123B1 (no) | Fremgangsmate for fremstilling av en biologisk aktiv myseproteinblanding | |
| US5451412A (en) | Biologically active undenatured whey protein concentrate as food supplement | |
| NO20110273A1 (no) | Næringsmessig komplett morsmelkerstatning | |
| US6667063B2 (en) | Nutritional or therapeutic supplement and method | |
| WO1999055326A1 (en) | Method of treatment of glutathione deficient mammals | |
| JP2003510367A (ja) | 腸粘膜疾患の治療及び予防におけるｔｇｆベータ及び成長因子の使用 | |
| CZ24999A3 (cs) | Farmaceutický prostředek | |
| Kassem | Future challenges of whey proteins | |
| CA2347172A1 (en) | Protein material for slow digestion and its use | |
| JP2008115194A (ja) | 癌の予防または治療用医薬組成物 | |
| US5849335A (en) | Composition and method for providing glutamine | |
| US5888552A (en) | Anti-cancer therapeutic compositions containing whey protein concentrate | |
| TWI364260B (en) | Nutritional formula comprising l-(+) lactic acid, its preparation method, and uses of l-(+) lactic acid therein | |
| EP1437945A1 (de) | Verwendung von cystathionine | |
| JPH1014534A (ja) | 栄養組成物 | |
| TW201822640A (zh) | 包含麥芽三糖之組成物，及使用彼以抑制由脫水方法導致之傷害的方法 | |
| RU2306715C1 (ru) | Сухая питательная смесь для диетологического питания | |
| Mc Donagh et al. | Milk and dairy products for better human health | |
| JP2016506754A (ja) | 食品組成物及び脱水症に対するその使用 | |
| JP2020195284A (ja) | 廃用性筋委縮予防・改善組成物 | |
| Jing | Effects of pressurization on the digestibility and glutathione inducing property of whey protein isolates in rats and mice | |
| CA2090377A1 (en) | Anti-cancer therapeutic compositions for prophylaxis or for treatment of chemically induced cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ACAPO AS, POSTBOKS 1880 NORDNES, 5817 BERGEN, NO |
|
| MK1K | Patent expired |